- Home
- AMBC vs OMER Comparison
AMBC vs OMER Comparison
Compare AMBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- OMER
- Stock Information
- Founded
- AMBC 1971
- OMER 1994
- Country
- AMBC United States
- OMER United States
- Employees
- AMBC N/A
- OMER N/A
- Industry
- AMBC Property-Casualty Insurers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- OMER Health Care
- Exchange
- AMBC Nasdaq
- OMER Nasdaq
- Market Cap
- AMBC 411.3M
- OMER 188.1M
- IPO Year
- AMBC 1991
- OMER 2009
- Fundamental
- Price
- AMBC $7.09
- OMER $3.93
- Analyst Decision
- AMBC Strong Buy
- OMER Strong Buy
- Analyst Count
- AMBC 1
- OMER 5
- Target Price
- AMBC $15.00
- OMER $18.00
- AVG Volume (30 Days)
- AMBC 935.0K
- OMER 934.1K
- Earning Date
- AMBC 08-04-2025
- OMER 08-06-2025
- Dividend Yield
- AMBC N/A
- OMER N/A
- EPS Growth
- AMBC N/A
- OMER N/A
- EPS
- AMBC N/A
- OMER N/A
- Revenue
- AMBC $253,912,000.00
- OMER N/A
- Revenue This Year
- AMBC N/A
- OMER N/A
- Revenue Next Year
- AMBC $17.41
- OMER $3,446.91
- P/E Ratio
- AMBC N/A
- OMER N/A
- Revenue Growth
- AMBC 125.08
- OMER N/A
- 52 Week Low
- AMBC $5.99
- OMER $2.95
- 52 Week High
- AMBC $13.64
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- AMBC 46.27
- OMER 60.74
- Support Level
- AMBC $6.87
- OMER $3.00
- Resistance Level
- AMBC $8.07
- OMER $3.25
- Average True Range (ATR)
- AMBC 0.30
- OMER 0.25
- MACD
- AMBC 0.03
- OMER 0.13
- Stochastic Oscillator
- AMBC 19.67
- OMER 95.61
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.